- Home
- HOND vs CDXS Comparison
HOND vs CDXS Comparison
Compare HOND & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOND
- CDXS
- Stock Information
- Founded
- HOND 2024
- CDXS 2002
- Country
- HOND United States
- CDXS United States
- Employees
- HOND N/A
- CDXS N/A
- Industry
- HOND
- CDXS Major Chemicals
- Sector
- HOND
- CDXS Industrials
- Exchange
- HOND NYSE
- CDXS Nasdaq
- Market Cap
- HOND 287.5M
- CDXS 332.0M
- IPO Year
- HOND 2024
- CDXS 2010
- Fundamental
- Price
- HOND $10.03
- CDXS $5.28
- Analyst Decision
- HOND
- CDXS Buy
- Analyst Count
- HOND 0
- CDXS 2
- Target Price
- HOND N/A
- CDXS $11.00
- AVG Volume (30 Days)
- HOND 1.3K
- CDXS 875.4K
- Earning Date
- HOND 01-01-0001
- CDXS 10-31-2024
- Dividend Yield
- HOND N/A
- CDXS N/A
- EPS Growth
- HOND N/A
- CDXS N/A
- EPS
- HOND N/A
- CDXS N/A
- Revenue
- HOND N/A
- CDXS $64,446,000.00
- Revenue This Year
- HOND N/A
- CDXS N/A
- Revenue Next Year
- HOND N/A
- CDXS $2.02
- P/E Ratio
- HOND N/A
- CDXS N/A
- Revenue Growth
- HOND N/A
- CDXS N/A
- 52 Week Low
- HOND $9.97
- CDXS $2.53
- 52 Week High
- HOND $11.57
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- HOND N/A
- CDXS 59.97
- Support Level
- HOND N/A
- CDXS $5.42
- Resistance Level
- HOND N/A
- CDXS $6.01
- Average True Range (ATR)
- HOND 0.00
- CDXS 0.39
- MACD
- HOND 0.00
- CDXS -0.05
- Stochastic Oscillator
- HOND 0.00
- CDXS 46.67
About HOND HCM II ACQUISITION CORP
HCM II Acquisition Corp is a blank check company.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.